Page last updated: 2024-08-21

thiazoles and Cytokine Release Syndrome

thiazoles has been researched along with Cytokine Release Syndrome in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Chen, Y; Ding, M; Jiang, X; Lan, K; Lavillete, D; Li, H; Li, S; Liu, Y; Shan, J; Shang, W; Shen, Z; Sun, Y; Tong, Y; Wang, R; Wang, Y; Wu, Y; Xiao, G; Xiong, R; Xu, K; Xu, L; Zhang, L; Zhao, Y; Zhao, Z; Zhu, L; Zou, G	1
Kelleni, MT	1

Other Studies

2 other study(ies) available for thiazoles and Cytokine Release Syndrome

Article	Year
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein & cell, 2020, Volume: 11, Issue:10 Topics: Animals; Antiviral Agents; Betacoronavirus; Binding Sites; Cell Line; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Dihydroorotate Dehydrogenase; Drug Evaluation, Preclinical; Gene Knockout Techniques; Humans; Hydroxybutyrates; Influenza A virus; Leflunomide; Mice; Mice, Inbred BALB C; Nitriles; Orthomyxoviridae Infections; Oseltamivir; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Pandemics; Pneumonia, Viral; Protein Binding; Pyrimidines; RNA Viruses; SARS-CoV-2; Structure-Activity Relationship; Thiazoles; Toluidines; Ubiquinone; Virus Replication	2020
NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert review of anti-infective therapy, 2022, Volume: 20, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Repositioning; Humans; Interferons; Interleukin-6; Nitro Compounds; Observational Studies as Topic; SARS-CoV-2; Thiazoles	2022

Article

Year

Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.

Protein & cell, 2020, Volume: 11, Issue:10

Topics: Animals; Antiviral Agents; Betacoronavirus; Binding Sites; Cell Line; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Dihydroorotate Dehydrogenase; Drug Evaluation, Preclinical; Gene Knockout Techniques; Humans; Hydroxybutyrates; Influenza A virus; Leflunomide; Mice; Mice, Inbred BALB C; Nitriles; Orthomyxoviridae Infections; Oseltamivir; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Pandemics; Pneumonia, Viral; Protein Binding; Pyrimidines; RNA Viruses; SARS-CoV-2; Structure-Activity Relationship; Thiazoles; Toluidines; Ubiquinone; Virus Replication

2020

NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.

Expert review of anti-infective therapy, 2022, Volume: 20, Issue:1

Topics: Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Repositioning; Humans; Interferons; Interleukin-6; Nitro Compounds; Observational Studies as Topic; SARS-CoV-2; Thiazoles

2022